

GE HEALTHCARE & CELL THERAPY

A TIMELINE BY EVOLUTION GLOBAL

GE acquires Disposable Bioreactor company Wave Biotech. **APR 2007**

GE acquires PAA Laboratories, a developer & supplier of cell culture media. **AUG 2011**

GE sublicense Stem Cell Theranostics intellectual property relating to the use of human induced pluripotent stem cells, enabling SCT to develop & manufacture cardiomyocytes derived from stem cells for use in drug discovery and toxicity. **JULY 2015**

Kite Pharma & GE announce strategic collaboration to automate manufacturing of engineered T-Cell therapies. **DEC 2015**

GE Ventures & Mayo Clinic launch Vitruvian Networks, which will provide therapy producers with a state-of-the-art software and manufacturing platform to bring the "Internet of things" to cell & gene therapies. **APR 2016**

GE acquires British cryogenic processing company Asymptote for an undisclosed amount. **APR 2017**

GE announces alliance with Geron Corporation to develop first generation human embryonic stem cell-based therapies. **JUNE 2009**

GE acquire Thermo Fisher's HyClone™ cell culture media and sera, and gene modulation and magnetic bead businesses. **JAN 2014**

The Cooperative Research Centre for Cell Therapy Manufacturing, GE Healthcare and Health Industries South Australia sign an agreement that will lay the foundation for a long-term partnership focussed on advancing Australia's cell therapy industry. **AUG 2015**

Toronto-based Centre for Commercialization of Regenerative Medicine announced, with GE and the Canadian government each investing \$20 million CAD. **JAN 2016**

GE acquires the Biosafe Group, a supplier of integrated cell bioprocessing systems, for an undisclosed amount. **JUNE 2016**

GE announce partnership with Cellular Biomedicine Group to develop CAR-T & stem cell production technologies to support its aim of creating 10,000 cancer therapies & 10,000 osteoarthritis treatments a year. **APR 2017**

